FMD has announced it has been granted patent 6,780,161. Issued on August 24, 2004, the patent covers the new technology of Twinheads(R) which uses two or more shock wave sources in the extracorp
Dangerous multi-drug-resistant bacteria are also developing immunity to hospital disinfectants and antiseptics, according to new research presented today at the Society for General Microbiology's 155th
NMT Medical today announced a favorable decision by the U.S. Patent and Trademark Office Board of Appeals relating to the Company's patent infringement actions against AGA Medical Corp.In D
The U.S. Patent and Trademark Office has issued the University of Utah U.S. patent No. U.S. 6,787,338 (the '338 patent) relating to methods of rapid nucleic acid amplification. The issuance of th
The physician who revolutionized screening methods for glaucoma nearly 20 years ago has patented a new device aimed at detecting glaucoma, a leading cause of blindness. Steven Feldon, M.D., director of the Eye Institute at the
Chiron Corporation has announced that it has reached a settlement with F. Hoffmann-La Roche (Roche) in a dispute over licensing fees and royalties that Chiron had asserted was owed to the company under
Scientists from MitoChroma Research have recently announced a patent pending discovery that could complement current medical management modalities for Type 2 Diabetes, insulin resistance and the se
Nanotechnology company pSivida has announced that its UK operating subsidiary pSiMedica Limited has been granted a further patent for BioSiliconTM. European Patent Number 1309309 relates to
MorphoSys Obtains Additional U.S. Patents on Antibody Technologies MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) announced today that the U.S. Patent & Trademark Office has
ChemGenex Pharmaceuticals has announced that it has filed for patent protection for a further five novel depression-associated gene targets discovered by its depression and anxiety research group.
"This patent further strengthens StemCells' leading position in the human neural stem cell field," said Martin McGlynn, President & CEO of StemCells Inc. "The patent covers human neural stem cell cultures derived from any source, including embryonic as well as fetal, neonatal and adult tissue. Next year, we intend to begin the process of testing the potential of our neural stem cells in the clinic to treat a wide range of diseases of, or injuries to, the central nervous system. As we have previously announced, we intend to file our first IND by the first quarter of 2005 for a clinical trial in Batten Disease, a rare, fatal neurodegenerative lysosomal storage disorder affecting the central nervous system," McGlynn added.
StemCells, Inc. is a biotechnology company focused on the discovery, development and commercialization of stem cell-based therapies to treat diseases of the nervous system, liver, and pancreas. The Company's stem cell programs seek to repair or repopulate neural or other tissue that has been damaged or lost as a result of disease or injury.
http://www.stemcellsinc.com